The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers
Open accessAbstract
A four-part, randomized, crossover study with healthy subjects evaluated the effects of gastric pH, the dosing frequency and prandial state, food consumption timing, and gastric motility on the absorption of posaconazole. In part 1, a single dose (SD) of posaconazole (400 mg) was administered alone or with an acidic beverage or a proton pump inhibitor (PPI), or both. In part 2, posaconazole (400 mg twice daily and 200 mg four times daily) was administered for 7 days with and without a nutritional supplement (Boost). In part 3, an SD of posaconazole (400 mg) was administered while the subjects were fasting and before, during, and after a high-fat meal. In part 4, an SD of posaconazole (400 mg) and the nutritional supplement were administered alone, with metoclopramide, and with loperamide. Compared to the results obtained with posaconazole alone, administration with an acidic beverage increased the posaconazole maximum concentration in plasma (Cmax) and the area under the concentration-time curve (AUC) by 92% and 70%, respectively, whereas a higher gastric pH decreased the posaconazole Cmax and AUC by 46% and 32%, respectively. Compared to the results obtained with posaconazole alone, posaconazole at 400 mg or at 200 mg plus the nutritional supplement increased the posaconazole Cmax and AUC by 65% and 66%, respectively, and by up to 137% and 161%, respectively. Administration before a high-fat meal increased the Cmax and the AUC by 96% and 111%, respectively, while administration during and after the meal increased the Cmax and the AUC by up to 339% and 387%, respectively. Increased gastric motility decreased the Cmax and the AUC by 21% and 19%, respectively. Strategies to maximize posaconazole exposure in patients with absorption difficulties include administration with or after a high-fat meal, with any meal or nutritional supplement, with an acidic beverage, or in divided doses and the avoidance of proton pump inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Self-citationPosaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases
van Burik, J.-A. H., Hare, R. S., Solomon, H. F., Corrado, M. L., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/500212 · Cited by 615
Posaconazole as Salvage Therapy for Zygomycosis
Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, I., Abzug, M. J., Anstead, G., Herbrecht, R., Langston, A., Marr, K. A., Schiller, G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.126-133.2006 · Cited by 555
Osthaus, K. E. (1920) · doi:10.5479/sil.182252.39088008237430 · Cited by 493
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491 · cited 1×
“Posaconazole is an extended-spectrum triazole antifungal with potent in vitro and in vivo activities against many clinically important yeasts and molds (16, 27).”
BackgroundCourtney, R., Wexler, D., Radwanski, E., Lim, J., & Laughlin, M. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 327
Raad, I. I., Hachem, R. Y., Herbrecht, R., Graybill, J. R., Hare, R., Corcoran, G., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/503425 · Cited by 302
Courtney, R., Pai, S., Laughlin, M., Lim, J., & Batra, V. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2788-2795.2003 · Cited by 299
Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
Self-citationBarone, J. A., Koh, J. G., Bierman, R. H., Colaizzi, J. L., Swanson, K. A., Gaffar, M. C., Moskovitz, B. L., Mechlinski, W., & Van de Velde, V (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.4.778 · Cited by 225
Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections
Raad, I. I., Graybill, J. R., Bustamante, A. B., Cornely, O. A., Gaona-Flores, V., Afif, C., Graham, D. R., Greenberg, R. N., Hadley, S., Langston, A., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/504328 · Cited by 217
Ezzet, F., Wexler, D., Courtney, R., Krishna, G., Lim, J., & Laughlin, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00006 · Cited by 208
Self-citationKrishna, G., Martinho, M., Chandrasekar, P., Ullmann, A. J., & Patino, H. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.12.1627 · Cited by 195
Self-citationThe effects of food and dose on the oral systemic availability of itraconazole in healthy subjects
Van Peer, A., Woestenborghs, R., Heykants, J., Gasparini, R., & Gauwenbergh, G. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558308 · Cited by 176
Zimmermann, T., Yeates, R. A., Laufen, H., Pfaff, G., & Wildfeuer, A. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00199879 · Cited by 173
Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole
Purkins, L., Wood, N., Kleinermans, D., Greenhalgh, K., & Nichols, D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01994.x · Cited by 163
Antacids Revisited: A Review of Their Clinical Pharmacology and Recommended Therapeutic Use
Maton, P. N., & Burton, M. E. (1999) · Drugs · doi:10.2165/00003495-199957060-00003 · Cited by 160
Keating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565110-00007 · Cited by 159
Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection
Krishna, G., Sansone‐Parsons, A., Martinho, M., Kantesaria, B. S., & Pedicone, L. D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00454-06 · Cited by 155
Self-citationPharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men
Courtney, R., Radwanski, E., Lim, J. M., & Laughlin, M. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.804-808.2004 · Cited by 154
Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses
Debruyne, D. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733010-00005 · Cited by 153
Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole
Chin, T. W., Loeb, M. B., & Fong, I. W. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1671 · Cited by 149
Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients
Gubbins, P. O., Krishna, G., Sansone‐Parsons, A., Penzak, S. R., Li, D., Martinho, M., & Anaissie, E. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-06 · Cited by 146
Self-citationHerbrecht, R. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00167.x · Cited by 144
van Burik, J. H., Hare, R. S., Solomon, H. F., Corrado, M. L., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · Cited by 140
Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H2 Blockers
Lange, D., Pavao, J. H., Wu, J., & Klausner, M. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04332.x · Cited by 136
Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole
Jaruratanasirikul, S., & Kleepkaew, A. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050280 · Cited by 128
de Velde, V. J. V., Peer, A. P. V., Heykants, J., Woestenborghs, R. J. H., Rooy, P. V., Beule, K. D., & Cauwenbergh, G. F. M. J. (1996) · PubMed · Cited by 116
Sansone‐Parsons, A., Krishna, G., Calzetta, A., Wexler, D. B., Kantesaria, B. S., Rosenberg, M. A., & Saltzman, M. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1881-1883.2006 · Cited by 104
Self-citationInfluence of food on the pharmacokinetics of ketoconazole
Daneshmend, T. K., Warnock, D. W., Ene, M., Johnson, E. M., Potten, M. R., Richardson, M. D., & Williamson, P. J. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.1.1 · Cited by 99
de Velde, V. J. S. V., Peer, A. P. V., Heykants, J., Woestenborghs, R. J. H., Rooy, P. V., Beule, K. D., & Cauwenbergh, G. F. M. J. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02973.x · Cited by 99
Lim, S. G., Sawyerr, A. M., Hudson, M., Sercombe, J., & Pounder, R. E. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00103.x · Cited by 93
Krishna, G., Abutarif, M. A., Xuan, F., Martinho, M., Angulo, D. A., & Cornely, O. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.10.1223 · Cited by 92
Self-citationEffect of food and gastric acidity on absorption of orally administered ketoconazole.
Lelawongs, P., Barone, J. A., Colaizzi, J. L., Hsuan, A. T. M., Mechlinski, W., Legendre, R., & Guarnieri, J. A. (1988) · PubMed · Cited by 89
Barone, J. A., Moskovitz, B. L., Guarnieri, J. A., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. M. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03856.x · Cited by 89
Shen, J. X., Krishna, G., & Hayes, R. N. (2006) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2006.06.011 · Cited by 84
Self-citationSaha, P., & Kou, J. H. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00113-2 · Cited by 79
Cited by
Jermain, S. V., Brough, C., & Williams, R. O. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.10.051 · Cited by 431
Current Concepts in Antifungal Pharmacology
Lewis, R. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0247 · Cited by 377
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Mitra, A., & Kesisoglou, F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400256h · Cited by 108
Metadata
- Authors
- Krishna, G., Moton, A., Ma, L., Medlock, M. M., & McLeod, J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-03
- Volume
- 53
- Issue
- 3
- Pages
- 958-966
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2117813373
- Cited by
- 349
- References
- 39
- FWCI
- 19.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.